OR-DIGIMARC-CORPORATION
22.2.2024 14:01:35 CET | Business Wire | Press release
Digimarc Corporation (NASDAQ: DMRC), the pioneer and global leader in digital watermarking technologies, today announced the wide availability and easy accessibility of Digimarc Recycle following successful pilots and testing in multiple countries worldwide. Digimarc Recycle represents a revolution in the sortation and recycling of plastic waste with the power to measurably advance the fight against plastic pollution, and this proven technology is now available for license by qualified partners for less than $1 per capita per year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240222238789/en/
Digimarc accelerates the global fight against plastic pollution. Digimarc Recycle is now widely available and easily accessible to unlock plastic circularity worldwide -- available for license by qualified partners for less than $1 per capita per year. (Graphic: Business Wire)
“After another year plagued with a lot of talk but little action in the fight to end plastic pollution, we are expanding our reach across stakeholders and geographies to encourage partners in the United States and around the world to join us on our mission to protect the planet,” said Digimarc President and CEO, Riley McCormack. “With today’s announcement, the technology proven to effect change is both accessible and affordable to a wide variety of partners across the recycling ecosystem without further delay.”
The Plastic Recycling Outlook
In the United States, the current ecosystem of plastics recycling does not work, as only 5-9% of plastics are fully recycled in the U.S. annually,1 which means that almost all plastics in the U.S. are discarded as waste.2 In 2021 alone, 51 million tons of plastic waste were generated in the U.S.3
One of the main reasons the world struggles to recycle plastic is due to the number of plastic variants that are created by industry and the limits of the optical sorting technology that exists at recycling facilities. Plastic packaging spans a huge range of types – from food- or skin-contact-grade to industrial-use plastics – and often contains multiple materials and layers, further compounding the challenges of sorting today. Current sorting technology can only identify, at a high level, some of the materials in each item, but it cannot identify the grade or complex composition of much of the material it works to sort. This means that it cannot sort based on specifications that would allow plastics to retain the value required to become truly circular – for example, determining if a plastic is food-grade. This disincentivizes producers to purchase and use recycled plastic as they are unable to acquire the plastic varieties and specifications they need.
Digimarc Recycle changes this dynamic by linking covert digital watermarks applied to plastic packaging to product information, including packaging composition, food or non-food grade plastic, product variant, brand, SKU, and more. Deploying digital watermarking, instead of solely relying on optical sortation, helps to create the variety, volume, and quality of recycled plastics needed for a viable circular economy to flourish. Roland Berger highlights Digimarc’s technology, digital watermarks, as a sorting technology that can “substantially improve the yield and quality of recyclates” – calling recyclates the “new gold.”4
Digimarc Recycle powers precise granular sortation of plastics, thereby increasing the opportunity for producers to purchase and repurpose higher quality recycled plastic that can compete on a level playing field with virgin materials. Digimarc’s digital watermarking technology makes this possible by identifying plastic packaging deterministically to any desired level of granularity including brand, SKU, SKU-variant, batch/lot, or even serialized item, none of which can be accomplished with current optical sorting technology or other proposed next-generation technologies. The application of Digimarc Recycle helps disincentivize the continued use of virgin plastics by producers and makes extended producer responsibility (EPR) schemes a more viable option to tackle the growing problem of plastic pollution.
“If we want producers to buy recyclate instead of continuing to use virgin plastic, we must improve the quality of plastic output at today’s recycling facilities and offer a real opportunity for closed-loop recycling. This is where Digimarc can help,” said McCormack. “Digital watermarking is a powerful, proven, and incredibly affordable solution to the plastic pollution crisis, and it is available today. We can talk about potential solutions, or we can commit to action. Our offer to license our groundbreaking technology to partners around the world underscores our belief that the time to act is now.”
Learn more about Digimarc Recycle at Digimarc.com or contact us at product@digimarc.com.
About Digimarc
Digimarc Corporation (NASDAQ: DMRC) is the pioneer and global leader in digital watermarking technologies. For nearly 30 years, Digimarc innovations and intellectual property in digital watermarking have been deployed at massive scale for the identification and the authentication of physical and digital items. A notable example of this is our partnership with a consortium of the world’s central banks to deter counterfeiting of global currency. Digimarc is also instrumental in supporting global industry standards efforts spanning both the physical and digital worlds. In 2023, Digimarc was named to the Fortune 2023 Change the World list and honored as a 2023 Fast Company World Changing Ideas finalist. Learn more at Digimarc.com.
| ____________________ | ||
1 |
Plastics: Material-specific data | US EPA. (n.d.). |
|
2 |
Sullivan, L. (2022, October 24). Recycling plastic is practically impossible - and the problem is getting worse. NPR |
|
3 |
Budryk, Z. (2022) US only recycled 5 percent of plastic waste in 2021: Greenpeace report, The Hill. |
|
4 |
Herweg, 0., Popa, D. (2023, March 15). Plastic Recyclates create new business opportunities for sector. Roland Berger |
|
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240222238789/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
